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Abstract
Background: Excessive time between diagnosis and initiation of tuberculosis (TB) treatment contributes to ongoing TB
transmission and should be minimized. In India, Revised National TB Control Programme (RNTCP) focuses on indicator start
of treatment within 7 days of diagnosis for patients with sputum smear-positive PTB for monitoring DOTS implementation.
Objectives: To determine length of time between diagnosis and initiation of treatment and factors associated with delays of
more than 7 days in smear-positive pulmonary TB.
Methods: Using existing programme records such as the TB Register, treatment cards, and the laboratory register, we
conducted a retrospective cohort study of all patients with smear-positive pulmonary TB registered from July-September
2010 in two districts in India. A random sample of patients with pulmonary TB who experienced treatment delay of more
than 7 days was interviewed using structured questionnaire.
Results: 2027 of 3411 patients registered with pulmonary TB were smear-positive. 711(35%) patients had .7 days between
diagnosis and treatment and 262(13%) had delays .15 days. Mean duration between TB diagnosis and treatment initiation
was 8 days (range = 0–128 days). Odds of treatment delay .7 days was 1.8 times more likely among those who had been
previously treated (95% confidence interval [CI] 1.5–2.3) and 1.6 (95% CI 1.3–1.8) times more likely among those diagnosed
in health facilities without microscopy centers. The main factors associated with a delay .7 days were: patient reluctance to
start a re-treatment regimen, patients seeking second opinions, delay in transportation of drugs to the DOT centers and
delay in initial home visits. To conclude, treatment delay .7 days was associated with a number of factors that included
history of previous treatment and absence of TB diagnostic services in the local health facility. Decentralized diagnostic
facilities and improved referral procedures may reduce such treatment delays.
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Introduction
India has the highest burden of Tuberculosis (TB) in the world,
accounting for approximately one fifth of the global incidence. An
estimated 2.3 million cases occur annually, of which 0.8 million
are sputum-smear positive [1]. Someone with untreated smear
positive pulmonary TB (PTB) can continue to infect others until
effective treatment is initiated. The best strategy to break the chain
of TB transmission is early diagnosis, initiation, and completion of
treatment [2,3].
Delays in patients reporting to health facilities with symptoms
and in health care workers reaching a diagnosis and initiation of
TB treatment all lead to continued transmission of infection.
Studies have documented the length of time from onset of
symptoms to the diagnosis of PTB. However, few studies have
described the extent to which the health system contributes to
delays that may occur from the time of PTB diagnosis to the start
of anti-tuberculosis treatment, and few have reported on risk
factors for these delays [4,5].
One of the indicators of the quality of DOTS implementation
under the Revised National TB Control Programme (RNTCP) of
India is start of treatment within 7 days of diagnosis for patients
with sputum smear-positive PTB [6]. Nationwide in 2010, 86% of
patients registered with smear-positive PTB were put on anti-
tuberculosis treatment within 7 days of diagnosis. This figure
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varies throughout the country, and in some districts only 60% of
patients were initiated on treatment within 7 days [7].
To better understand factors associated with delays between
diagnosis and treatment, we conducted a study in two districts of
India to assess the length of time between diagnosis and treatment
of smear-positive PTB. We also sought to identify risk factors
associated with delays of more than 7 days from the patient’s
perspective.
Methods
Study Design
This was a retrospective survey involving a record review of TB
registers, laboratory registers and treatment cards of all patients
with smear-positive pulmonary TB registered from July-Septem-
ber 2010 in two districts in India. This was followed by structured
cross-sectional interviews of a random sample of patients with
PTB. Patients were using simple random sampling from a
complete list of patients who experienced a delay of more than
7 days between diagnosis and start of treatment.
Setting
We conducted the study in two rural districts of two states in
India: Bardhaman, West Bengal (population 7.8 million) and
Nalgonda, Andhra Pradesh (population 3.5 million).
In India there are different types of health care institutions
where pulmonary TB is diagnosed using sputum smear examina-
tion. The institutions vary from tertiary level hospitals such as
Medical colleges, District TB centers at district level, Tuberculosis
Units at sub district level, and Peripheral Health Institutions
(PHIs). There are two types of PHIs, with and without sputum
smear microscopy services. Microscopy services are placed in the
busier government health facilities, and cover approximately
100,000 population. All persons suspected of having PTB are
referred to a Designated Microscopy Centre (DMC) for sputum
smear examination where two sputum samples (one spot and one
early morning) are collected and examined for acid-fast bacilli
(AFB) using light binocular microscopy. People suspected of
having PTB seen in a PHI without microscopy must travel to a
microscopy center for sputum smear examination and bring those
results back to the local area PHI for the diagnosis and
categorization. People residing in the area of a PHI with
microscopy have sputum smear examination, categorization, and
diagnosis carried out at the same location.
Providers at PHI’s prescribe but do not initiate anti-TB
treatment. All patients report to their local area DOT Centers to
start treatment as shown in Fig. 1. DOT centers are highly
decentralized. They are not stand–alone facilities, but rather serve
as any treatment delivery point from where a DOT provider
operates (e.g. home of a village health worker, community
volunteer, local sub-centre where a nurse operates, etc). The
Health worker covering the area of the DOT Center collects the
anti-TB medication from the PHI, conducts an Initial Home visit
(IHV) for verifying the address, and counsels the patient. S/he then
identifies a DOT Provider for the patient and starts the patient on
treatment. The steps involved from diagnosis to appropriate
treatment for both those initially seen at a PHI with microscopy
and those seen in a PHI without microscopy are the same except for
the fact that those seen in a PHI without sputum microscopy must
travel to get their sputum examined at a DMC [8].
Study Participants
This study included all patients with sputum smear positive PTB
registered from 1st July to 30th September 2010 in the participating
two districts. Any patient with at least one sputum smear found to
be positive for acid-fast bacilli was defined as having smear positive
PTB.
Variables and Data Collection, Data Analysis and Statistics
The number of days between the date of diagnosis of PTB and
the date of initiation of treatment was collected from the
laboratory register, the TB register and treatment cards. The
outcome variable was delayed treatment initiation, defined as
treatment starting more than 7 days after TB diagnosis. Exposure
variables included: age, sex, health system level of microscopy
facility [District TB Centre (DTC-DMC), TB Unit (TU-DMC),
DMC of other districts, Medical College DMC, other DMC], type
of TB [(new smear positive (NSP), retreatment TB (RT)], and
presence of microscopy at the health facility where the patient was
diagnosed (PHI with or without microscopy). We used crude and
adjusted odds ratios and 95% confidence limits to assess the
relation between these categorical variables and delayed initiation
of treatment. For univariate analysis, we calculated maximum
likelihood estimates of matched odds ratios and their exact 95%
confidence intervals. We calculated P-values using the Mantel-
Haenszel method or Fisher’s exact test. We determined a P-value
of ,0.05 was statistically significant and all tests of significance
were two tailed. Independent variables which were significantly
associated with our outcome of interest during the crude analyses
were all included in one logistic regression model to calculate
adjusted associations.
Structured Interviews of a Sample of Patients with
Delayed Treatment Initiation
Using simple random sampling we selected 75 patients from
each district (150 in total) who had delayed treatment initiation.7
days. We interviewed patients using a structured questionnaire to
gather additional descriptive information regarding delayed
initiation of treatment that was unavailable from routine records.
Participants were interviewed at their home and were still
receiving medication for TB. Interviews were conducted in
October, November, and December of 2010. Repeated visits
were made if the patients were not available during the first house
visits, all patients were interviewed during this period. Exposure
variables collected were duration between first and second sample
collection, duration in days between second sputum collection and
collection of smear examination reports, duration between report
collection and initial home visit by health worker, and duration
between initial home visit and initiation of treatment.
Ethical Considerations
We received informed consent from all patients that participat-
ed in the interviews. Ethical approval was obtained from the
Institutional Ethics Committee of National Tuberculosis Institute
(NTI), Bangalore and the Ethics Advisory Group of the
International Union against Tuberculosis and Lung Disease.
Results
There were 2027 patients with PTB (79% male), whose median
age was 39 years. The distribution of time from diagnosis to
initiation of treatment is shown in Table 1. Overall, 711 (35%)
patients were initiated on treatment after 7 days, and this included
262 (13%) with treatment delay of .15 days.
Factors associated with delays in initiation of treatment are
shown in Table 2. On univariate and multivariate analyses, the
main factors associated with delay were residing in a non-DMC
Delayed Initiation of Treatment
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PHI area, undergoing diagnostic microscopy outside their TB
Unit/District, and previously being treated for TB.
Demographic and clinical factors among the randomly selected
participants did not differ significantly from those of the entire
study population. The patient and provider related reasons for
delays in initiation of treatment are reported from patient
interviews with delay in these districts are shown in Table 3.
Patients who had treatment delay .7 days reported that delays
were mainly due to lack of smear microscopy in the original clinic,
reluctance to be put on injectable drugs, seeking a second opinion
after the diagnosis and delays in obtaining the reports. Again
patients also attributed treatment delay to transportation of drugs
from the Peripheral Health Institution to the DOT provider and
the compulsory initial home visit by the health worker.
Discussion
This is one of the first studies conducted under programmatic
settings in India to address delayed initiation of TB treatment after
the time of diagnosis. Four our data from two districts in India, we
learned that more than one-third of patients with smear-positive
TB had treatment delayed more than 7 days after diagnosis,
including 13% with delayed-treatment more than 15 days. Not
surprisingly we documented that treatment was more likely to be
delayed when diagnosis and treatment were separated. Where the
patient lived near the microscopy center performing TB diagnosis,
they were quickly initiated on treatment. Where the patient was
diagnosed at a center without microscopy or had to be referred for
treatment to a local DOT center, delay was more likely to occur.
Programme procedural barriers like sharing of timely results with
the referring doctor or transportation of the drugs to the DOT
center, may exacerbate this geographical association. However,
patients who experienced treatment delays frequently reported
seeking second opinions especially from private sector which have
presence in the local areas, suggesting that treatment delay was
driven by more than geography or procedural barriers. Limited
confidence in their TB diagnosis may also have played a role.
In few studies conducted elsewhere the core problem in delay of
diagnosis and treatment seemed to be a vicious cycle of repeated
visits at the same healthcare level, resulting in nonspecific
antibiotic treatment and failure to access specialized TB services
[4].
There are a number of important implications of this study for
tuberculosis control in India. First, patients residing in areas where
they do not have diagnostic facilities have a greater chance of
delay in the initiation of their treatment, and this is almost
certainly due to problems of access that involve distance and time.
While microscopy services are already decentralized to the
100,000 person level in India, further decentralizing of laboratory
diagnosis in districts may help to reduce delay. This would have to
be balanced by considerations in maintaining a sufficient
laboratory workload to maintain laboratory technician compe-
tence.
Second, patients who are diagnosed outside their own area have
an increased likelihood of delay. The RNTCP is meant to adhere
to a mechanism of referral and feedback when a patient is
diagnosed outside his/her area. This mechanism, based on paper
exchange, is time-consuming. Why patients sometimes seek care
outside their local area, despite service availability, was not
addressed in this study. In this study, the duration between TB
diagnosis and treatment initiation was 0–128 days compared to the
total delay in diagnosis of pulmonary tuberculosis of 25–185 days
in other studies [5].
Figure 1. Diagram showing the initiation of TB treatment at DOT centers of Peripheral Health Institutions (PHIs).
doi:10.1371/journal.pone.0039040.g001
Table 1. Time from diagnosis to initiation of TB treatment in
patients with smear positive TB under RNTCP, during July–
Sept 2010, in Bardhaman (West Bengal) and Nalgonda
(Andhra Pradesh) districts.
Number of days Number of patients (%)
0 to 7 1316 (65)
8 to 14 449(22)
15 to 21 123(6)
Above 21 139(7)
Total 2027(100)
doi:10.1371/journal.pone.0039040.t001
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Third, the transportation of drugs in the patient-wise box for a
diagnosed patient to a local DOT center after diagnosis may
contribute to delay; this could be addressed through decentraliza-
tion of treatment stocks, using general health system staff for same-
day transportation of the treatment box, or issuing some initial
treatment doses from the point of diagnosis to minimize any
treatment delay. The Provider related reasons [Table 3] may be
due to the vacancy of the staff in that particular area or the staff
Table 2. Factors associated with delayed initiation of treatment of more than 7 days among patients with smear positive TB under
RNTCP, during July–Sept 2010, in Bardhaman (West Bengal) and Nalgonda (Andhra Pradesh) districts.
Total
Delayed initiation of
treatment .7days Odds ratio (95% CI)
Adjusted odds ratio
(95% CI)
Age group (in years) n (%)
0–14 22 7 (32) 0.6 (0.2–1.7) –
15–34 732 251 (34) 0.7 (0.5–1) –
35–54 852 301 (35) 0.8 (0.5–1.1) –
55–65 299 101 (34) 0.7 (0.5–1.1) –
$65 122 51 (42) Reference
Sex
Male 1597 574 (36) 1.2 (1.0–1.5) 1.1 (0.9–1.4)
Female 430 137 (32) Reference
History of prior treatment .1 mo
Yes (Re-treatment case) 507 229 (45) 1.8 (1.4–2.2) 1.8 (1.5–2.3)
No (New case) 1520 482 (32) Reference
HIV-Status
Positive 50 16 (32) 1.0 (0.5–1.8) 0.9 (0.5–1.8)
Unknown 863 339 (39) 1.4 (1.1–1.7) 1.6 (1.3–1.9)
Negative 1114 356 (32) Reference
Type of Diagnostic Facility
Medical College 195 68 (35) 1.2 (0.8–1.7) 1.6 (1.1–2.4)
Outside district-DMC* 85 39 (46) 1.7 (1.1–2.6) 1.7 (1.1–2.7)
Outside TU-DMC 23 18 (78) 7.1 (2.6–19.3) 7.8 (2.8–21.6)
TU-DMC 824 280 (34) 1.0 (0.8–1.2) 1.1 (0.9–1.3)
Other PHI DMC 900 306 (34) Reference
Microscopy in treating unit
Without microscopy 783 316 (40) 1.5 (1.2–1.8) 1.6 (1.3–1.9)
With microscopy 1244 395 (32) Reference
*TU – tuberculosis unit, DMC – Designated Microscopy Centre, PHI – peripheral health institution.
doi:10.1371/journal.pone.0039040.t002
Table 3. Major reasons for delay in initiation of treatment as reported from 150 patients who had a delay in the diagnosis of smear
positive TB between July–Sept 2010, in Bardhaman (West Bengal) and Nalgonda (Andhra Pradesh) districts.*
Patient related reason:
1. Lack of smear microscopy in the original clinic, with need of referral to a microscopy centre for testing, and loss of time after results during referral back to the original
clinic. (130/150)#
2. Seeking a second opinion after the diagnosis has been established. (48/150)#
3. Reluctance to be put on Re-treatment regimen (which contains injectable drugs). (30/150)#
4. Time taken from the first sputum collection at the Designated Microscopy Centre and the collection of reports. (28/150)#
Provider related reasons (Patient’s perspectives of provider related factors):
1. Delay in transport of drugs from the Peripheral Health Institution to the DOT centers where the patient is supposed to start his DOT.
2. Delay in programme-mandated initial Home visits by the health workers before the start of treatment.
*Reasons are listed based on the frequency with which they were reported by patients (i.e., the first reason listed was most frequently cited, followed by the second, the
third, etc.).
#Multiple answers given by the patients.
doi:10.1371/journal.pone.0039040.t003
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may be pre-occupied with other health related activities in the
PHI.
Fourth, retreatment patients are more likely to experience
delays than new patients. There may be a number of contributing
factors to this observation, including lack of confidence in
diagnosis, seeking second opinions, side effects experienced with
previous drug intake, or fear of injectable streptomycin. Such cases
should be treated with more concern knowing that they may have
had negative previous treatment experiences. In addition, patients
previously-treated for TB experienced more treatment delay than
new patients, which some patients attributed to concern about
having to receive an injectable drug. Though the potential of
Private sector laboratories cannot be undermined in the study
areas none of the laboratories have been recognized as Designated
Microscopy centres by RNTCP. It is undoubted that involving
labs in the Public Private Partnership mode could decrease the gap
in accessibility to TB diagnosis in the districts.
Finally, a recent study on health seeking behavior of persons
with symptoms typical of pulmonary TB [9] showed that patients
may not seek health care services at certain centers which are not
patient friendly. Ensuring that health care facilities are more
approachable and accessible could help patients make more use of
these facilities.
Limitations
This was an operational study and therefore subject to the usual
limitations of such research. We could only assess variables which
are routinely collected in the registers, and there may be other
factors related to delay which we were not able to assess.
Furthermore we could not differentiate between patient related
delay and provider related delays from the register reviews. We
were reassured, however, by the concordance between the findings
from record analysis and patient interviews. Finally, as there was
no comparison group for the patients who completed the
structured interview, we cannot confirm which patient-reported
factors were related to delayed treatment initiation. Rather, results
from these interviews merely suggest factors related to delayed
treatment initiation which deserves further study. Recall bias could
exist based on the duration between treatment initiation and time
of interview. Health worker interviews would have provided
insights into provider related delays. To conclude, treatment delay
.7 days in Nalgonda and Bardhaman district were associated with
the logistic and geographical separations of diagnosis and
treatment. To reduce treatment delay, diagnostic facilities should
be made more accessible to the patients. The existing system of
referral and feedback for patients diagnosed outside their areas
needs to be strengthened. More intensified pretreatment counsel-
ing on the necessity of early initiation of treatment is required.
Initial home visits need to be undertaken and drugs need to be
transported to the DOT centers as soon as the patient is diagnosed
at the PHI. Reassuring a patient and providing supportive
treatment to all patients, especially retreatment cases, must take
account of the practice of seeking second opinions and the
hindrances experienced due to side effects experienced during
previous drug administration.
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